XML 58 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Total Stock-Based Compensation Expense Included in Company's Consolidated Statements of Income and Comprehensive Income

The total stock-based compensation expense included in the Company’s consolidated statements of income and comprehensive income was as follows:

 

     Three Months Ended June 30,      Six Months Ended June 30,  
     2016      2015      2016      2015  

Cost of revenues

   $ 890       $ 578       $ 1,330       $ 1,057   

Research and development expense

     689         428         1,063         850   

Selling, general and administrative expense

     8,937         2,560         12,275         4,871   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total pre-tax stock-based compensation expense

   $ 10,516       $ 3,566       $ 14,668       $ 6,778   
  

 

 

    

 

 

    

 

 

    

 

 

Summary of Activity for RSUs

The following table presents the activity for RSUs under the Plan:

 

     Six Months Ended June 30, 2016  
     Non-vested RSUs      Weighted Average
Grant Date
Fair value
 

Non-vested RSUs – beginning of period

     733,162       $ 30.94   

Assumed shares from Newport Merger

     324,075         35.01   

Granted

     695,284         35.17   

Vested

     (429,484      31.17   

Forfeited or expired

     (37,585      32.56   
  

 

 

    

 

 

 

Non-vested RSUs – end of period

     1,285,452       $ 34.19   
  

 

 

    

 

 

Summary of Activity for Outstanding and Exercisable Stock Appreciation Rights

At June 30, 2016, the Company’s outstanding and exercisable stock appreciation rights, the weighted-average base value, the weighted average remaining contractual life and the aggregate intrinsic value thereof, were as follows:

 

     Number
of shares
     Weighted
Average Base
Value
     Weighted
Average
Remaining
Contractual
Life (years)
     Aggregate
Intrinsic
Value
 

Stock appreciation rights outstanding

     746,184       $ 27.87         4.3       $ 11,334   

Stock appreciation rights exercisable

     506,436       $ 26.57         3.7       $ 8,349